Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHDY.L Regulatory News (HDY)

  • There is currently no data for HDY

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE ON CONDITIONAL SALE OF HEPI

15 Jul 2019 13:57

RNS Number : 5685F
Hardy Oil & Gas plc
15 July 2019
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014 ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

15 July 2019

 

Hardy Oil and Gas plc

(LSE: HDY)

 

UPDATE ON CONDITIONAL SALE OF HEPI

 

Hardy Oil and Gas plc ("Hardy" or "Company"), the oil and gas exploration and production company focussed in India, announced on 1 July 2019 ("Initial Sale Announcement") that it had entered into a conditional share purchase agreement ("HOEC SPA") to sell its wholly-owned subsidiary, Hardy Exploration & Production (India) Inc. ("HEPI") to Hindustan Oil Exploration Company Limited ("HOEC") for consideration of US$1,500,000 in cash ("HOEC Sale").

Following the release of the Initial Sale Announcement, the Company received an unsolicited offer of US$3,000,000 in cash from Invenire Energy Private Ltd ("Invenire") to acquire HEPI ("Invenire Sale"). The Company now announces, that following this offer, the Company has entered into a second conditional share purchase agreement ("Invenire SPA") to sell HEPI to Invenire.

Unless defined herein, defined terms used in this announcement shall have the same meaning as in the Initial Sale Announcement.

As outlined in the Initial Sale Announcement (in particular the section titled "Background to and reasons for the Transaction"), due to the difficulties arising from the litigation and disputes associated with the Assets, the Directors have concluded that disposing of HEPI is in the best interests of the Company and its shareholders. HEPI has been reliant on the Company to provide it with funds for it to continue to trade and fund the ongoing litigation and disputes and such funding obligations are a significant financial burden on Hardy, particularly when it is not certain when, or if, any of the Assets will start generating returns for shareholders.

The offer from Invenire of US$3,000,000 for the acquisition of HEPI is twice the amount agreed to be paid by HOEC pursuant to the terms of the HOEC SPA. Accordingly, the Board unanimously believes that it is in the best interests of the Company and its shareholders to maximise the value to be realised by the sale of HEPI and to therefore proceed with the sale of HEPI to Invenire.

As with the HOEC Sale, the Invenire Sale remains of sufficient size relative to the Group to constitute a class 1 transaction for the purposes of the Listing Rules and the Invenire Sale is therefore conditional upon the approval of the Company's shareholders. The Company is in the process of preparing a circular in order to seek approval of the Company's shareholders to the Invenire Sale and to the associated proposed transfer of the Company's listing from the Premium Segment of the Official List to the Standard Segment ("Transfer of Listing") (resulting from the Group no longer having an independent business under FCA guidelines). It is expected that the circular will be posted to the Company's shareholders, together with a notice of an extraordinary general meeting, within the next few weeks.

Under the terms of the HOEC SPA, the Company has agreed to use its reasonable endeavours to obtain shareholder approval for the HOEC Sale and to send a circular to shareholders convening an extraordinary general meeting by no later than 30 September 2019. However, these obligations are subject to the Directors' fiduciary duties. Having regard to the significantly higher value of the offer from Invenire, the Board have been advised that to proceed with the HOEC Sale would be in breach of the Directors' fiduciary duties.

Further announcements will be made by the Company in due course regarding the Invenire Sale, any competing bids or revised offers for HEPI and the Transfer of Listing.

Impact of the Invenire Sale

Following completion of the Invenire Sale ("Completion"), HEPI will cease to be part of the Group and the Company will be a "cash shell" with no subsidiaries or operational assets. Given the Company will operate as a "cash shell" post-Completion, the approval of the Company's shareholders will be sought in relation to the Transfer of Listing. Completion of the Invenire Sale requires resolutions approving both the Invenire Sale and the Transfer of Listing being passed by the Company's shareholders.

Principal Terms of the Invenire Sale

Pursuant to the terms of the Invenire SPA, Invenire has agreed to acquire the whole of the capital stock of HEPI for cash consideration of US$3,000,000. The consideration is being held by the Company's solicitors and will be released to Hardy on Completion.

Completion of the Invenire Sale is conditional only on the Company's shareholders passing (i) a resolution approving the Invenire Sale; and (ii) a resolution approving the Transfer of Listing. The Company is required, subject to the fiduciary duties of its Directors, to use its reasonable endeavours to satisfy this condition by no later than 7 October 2019. Neither the Company nor Invenire has any right to terminate the Invenire SPA between signing and Completion and the Invenire SPA is not subject to any other conditions.

The Company is not giving any warranties, indemnities or tax covenant to Invenire under the terms of the Invenire SPA except for warranties as to title to the shares in HEPI, HEPI's share capital and its capacity to enter into the Invenire SPA and sell the shares.

As reported in the Initial Sale Announcement, as a result of the Company's continued financing of HEPI, as of 30 June 2019, HEPI owed the Company approximately US$124 million by way of an intra-group debt ("Intra-Group Debt"). As part of the Invenire Sale the Company proposes to (i) capitalise substantially all of the Intra-Group Debt at Completion in consideration of the issue by HEPI of further shares in HEPI; and (ii) waive its rights to the repayment of the remainder of Intra-Group Debt such that the remainder of Intra-Group Debt will be written off and HEPI will not have any indebtedness to the Company following Completion ("Capitalisation and Waiver"). This means that the Intra-Group Debt will no longer appear in the Company's financial statements. In the event that Completion does not occur, the Company will not proceed with the Capitalisation and Waiver and the Intra-Group Debt will remain outstanding.

Information on Invenire

Invenire is an independent upstream oil and gas company with producing assets in South East Asia, including India. Access to talent, technology and capital ably positions Invenire to pursue exploration and production (E&P) opportunities in the current market environment. Invenire has been successful in building a portfolio of assets through acquisitions and also through direct participation in the Government bidding rounds.

Current Trading, Use of Net Proceeds and Future Prospects

As reported in the Initial Sale Announcement, given the developments outlined in the 2019 Preliminary Final Results Announcement, the Directors remain of the view that attempting to realise some value in respect of the Assets by way of a disposal of HEPI is in the best interests of the Company and its shareholders. Following Completion, the Company will transfer its listing from the Premium Segment to the Standard Segment of the Official List and the net proceeds from the Invenire Sale will be retained to provide additional working capital for the Company and will be added to the Company's cash resources for the Company to seek new investment opportunities.

Commenting on the Invenire Sale, Alasdair Locke, Chairman, said: "The Board unanimously considers that the Invenire Sale is in the best interests of all shareholders. Not only will it reduce significantly the outgoings associated with HEPI remaining part of the Group but the price secured by the Board is at a substantially higher price than that offered by HOEC. The Invenire Sale will remove a major element of uncertainty for investors and provide the Company with a significant increase in the amount of its working capital enabling the Company to seek new investment opportunities."

 

For further information please visit www.hardyoil.com or contact:

Hardy Oil and Gas plc

012 2461 2900

Ian MacKenzie, Chief Executive Officer

Richard Galvin, Treasurer &

Corporate Affairs Executive

 

 

 

Arden Partners plc

020 7614 5900

Ciaran Walsh

Steve Douglas

Equity Sales: James Reed-Daunter

 

 

Tavistock

020 7920 3150

Simon Hudson

Barney Hayward

 

 

 

 

-ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDEAAXSFSLNEFF
Date   Source Headline
24th Nov 20084:40 pmRNSPrice Monitoring Extension
18th Nov 200812:08 pmRNSNotice of Interest in Shares
18th Nov 20088:26 amRNSNotifications of Major Interests in Shares
12th Nov 20084:43 pmRNSSecond Price Monitoring Extn
12th Nov 20084:38 pmRNSPrice Monitoring Extension
7th Nov 20084:43 pmRNSNOTIFICATION OF MAJOR INTERESTS IN SHARES
5th Nov 20087:00 amRNSInterim Management Statement
30th Oct 20084:03 pmRNSNotice of Major Interest in Shares
28th Oct 20087:00 amRNSOperational Update - PY-3 Phase III
27th Oct 20087:00 amRNSBoard Appointment
24th Oct 20084:38 pmRNSPrice Monitoring Extension
13th Oct 200811:09 amRNSDirector's Dealing
7th Oct 20084:42 pmRNSSecond Price Monitoring Extn
7th Oct 20084:40 pmRNSPrice Monitoring Extension
19th Sep 20084:50 pmRNSSecond Price Monitoring Extn
19th Sep 20084:37 pmRNSPrice Monitoring Extension
26th Aug 20087:05 amRNSInterim Results
26th Aug 20087:00 amRNSGS-01 Update
1st Aug 200810:20 amRNSNOTICE OF MAJOR INTERESTS IN
28th Jul 20087:00 amRNSNotice of Results
16th Jul 20087:00 amRNSOperational Update
11th Jul 20087:00 amRNSBlock Listing
9th Jul 20083:42 pmRNSTotal Voting Rights
7th Jul 20083:05 pmRNSNotice of Major Interests
29th May 200811:08 amRNSAGM Statement
29th May 20088:09 amRNSNotification of shares
27th May 20087:00 amRNSAnnual Information Update
19th May 20082:12 pmRNSInterim Management Statement
30th Apr 20087:01 amRNSAnnual Report & Notice of AGM
30th Apr 20087:00 amRNSCommencement Of Drilling
17th Apr 20087:00 amRNSDirectors' Dealings
10th Apr 20087:01 amRNSPreliminary Results
3rd Apr 20087:01 amRNSNigeria Farmout
3rd Apr 20087:01 amRNSNew India Licence Grant
2nd Apr 20081:01 pmRNSNotice of Major Intersets
1st Apr 20083:41 pmRNSDrilling Update
1st Apr 200810:10 amRNSNotice of Results
19th Mar 20084:58 pmRNSTR:1 Notice of Major Interest
13th Mar 20087:01 amRNSFTSE Review
11th Mar 20084:09 pmRNSMajor Interests in Shares
7th Mar 200811:37 amRNSMajor Interests in Shares
20th Feb 20088:05 amRNSFirst Day of Dealings
15th Feb 20082:17 pmRNSListing Update
13th Feb 20087:01 amRNSActivity Update
4th Feb 200812:30 pmRNSResult of EGM
22nd Jan 20083:24 pmRNSBlock Admission
18th Jan 20082:37 pmRNSHolding(s) in Company
11th Jan 20082:36 pmRNSListing Update
11th Jan 20087:04 amRNSProposed Transfer of Listing
11th Jan 20087:02 amRNSNotice of EGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.